Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.omtn.2020.05.030 http://scihub22266oqcxt.onion/10.1016/j.omtn.2020.05.030 32585623!7321785!32585623     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32585623&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Mol+Ther+Nucleic+Acids 2020 ; 21 (ä): 147-155 Nephropedia Template TP {{tp|p=32585623|t=2020. CRISPR-Cas13a Inhibits HIV-1 Infection |pdf=|usr=}}{{32585623}} gab.com Text CRISPR-Cas13a Inhibits HIV-1 Infection JO: Mol Ther Nucleic Acids http://www.kidney.de/pget.php?&tw=1&pmid=32585623 #FOAvip CRISPR-Cas provides bacteria and archaea with immunity against invading phages and foreign plasmid DNA and has been successfully adapted for gene editing in a variety of species. The class 2 type VI CRISPR-Cas effector Cas13a targets and cleaves RNA, providing protection against RNA phages. Here we report the repurposing of CRISPR-Cas13a to inhibit human immunodeficiency virus type 1 (HIV-1) infection through targeting HIV-1 RNA and diminishing viral gene expression. We observed strong inhibition of HIV-1 infection by CRISPR-Cas13a in human cells. We showed that CRISPR-Cas13a not only diminishes the level of newly synthesized viral RNA, either from the transfected plasmid DNA or from the viral DNA, which is integrated into cellular DNA, but it also targets and destroys the viral RNA that enters cells within viral capsid, leading to strong inhibition of HIV-1 infection. Together, our results suggest that CRISPR-Cas13a provides a potential novel tool to treat viral diseases in humans. Twit Text FOAVip CRISPR-Cas13a Inhibits HIV-1 Infection ????Mol Ther Nucleic Acids http://www.kidney.de/pget.php?&tw=1&pmid=32585623 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32585623 #FOAvip English Wikipedia <ref>{{Cite pmid|32585623}}</ref> CRISPR-Cas13a Inhibits HIV-1 Infection #MMPMID32585623 Yin L; Zhao F; Sun H; Wang Z; Huang Y; Zhu W; Xu F; Mei S; Liu X; Zhang D; Wei L; Cen S; Hu S; Liang C; Guo F Mol Ther Nucleic Acids 2020[Sep]; 21 (ä): 147-155 PMID32585623show ga CRISPR-Cas provides bacteria and archaea with immunity against invading phages and foreign plasmid DNA and has been successfully adapted for gene editing in a variety of species. The class 2 type VI CRISPR-Cas effector Cas13a targets and cleaves RNA, providing protection against RNA phages. Here we report the repurposing of CRISPR-Cas13a to inhibit human immunodeficiency virus type 1 (HIV-1) infection through targeting HIV-1 RNA and diminishing viral gene expression. We observed strong inhibition of HIV-1 infection by CRISPR-Cas13a in human cells. We showed that CRISPR-Cas13a not only diminishes the level of newly synthesized viral RNA, either from the transfected plasmid DNA or from the viral DNA, which is integrated into cellular DNA, but it also targets and destroys the viral RNA that enters cells within viral capsid, leading to strong inhibition of HIV-1 infection. Together, our results suggest that CRISPR-Cas13a provides a potential novel tool to treat viral diseases in humans. äCRISPR-Cas13a Inhibits HIV-1 Infection (epmc).pdf DeepDyve Pubget Overpricing